08:00 , Feb 18, 2013 |  BioCentury  |  Emerging Company Profile

Signum: Rosacea double play

Therapies on the market or in development for rosacea treat either the symptomatic flushing or the inflammatory skin lesions. Signum Dermalogix Inc.'s lead small molecule isoprenylcysteine analog could treat both aspects of rosacea by targeting...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Valeant, Intendis GmBH sales and marketing update

VRX's Valeant Pharmaceuticals Ltd. unit received exclusive rights to distribute Intendis' dermatological products in the U.K. The products include rosacea treatment Finacea azelaic gel and acne treatment Skinoren 20% azelaic acid cream. Valeant Pharmaceuticals International...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Company News

Valeant, Schering sales and marketing update

Valeant Pharmaceuticals International (VRX), Costa Mesa, Calif.   Schering AG (FSE:SCH; SHR), Berlin, Germany   Business: Dermatology   VRX will distribute dermatological products from SCH's Intendis GmbH unit in the U.K., including rosacea treatment Finacea azelaic...
08:00 , Dec 15, 2003 |  BC Week In Review  |  Clinical News

Finacea topical 15% azelaic acid gel regulatory update

The European Commission (EC) granted marketing approval for Finacea to treat papulopustular rosacea. The topical gel already is approved in the EU to treat mild to moderate papular-pustular acne of the facial area and in...
08:00 , Dec 12, 2003 |  BC Extra  |  Company News

EC approves Schering's Finacea

The European Commission (EC) granted marketing approval to Schering (FSE:SCH; SHR) for its Finacea 15% azelaic acid gel to treat papulopustular rosacea. The topical gel already is approved in the EU to treat mild to...
08:00 , Jan 6, 2003 |  BC Week In Review  |  Clinical News

Finacea azelaic acid gel regulatory update

The FDA granted marketing approval for Finacea gel to topically treat inflammatory papules and pustules of mild to moderate rosacea. A cream formulation of azelaic acid is marketed in the U.S. and Europe under the...
07:00 , Sep 7, 1993 |  BioCentury  |  Product Development

Cellegy's cross-over skin treatment

In the old model, an insult to the skin passed through the outer dead layer of cells and elicited a response in the dermis, which then was reflected on the surface. In fact, many skin...